Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × Immune Checkpoint Inhibitors × 90 days × Clear all

Carcinoma, Non-Small-Cell Lung

NCT07405086 2026-05-22

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT05522660 2026-04-27

USZ-STRIKE

Phase 3 Recruiting

180 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02973789 2026-03-18

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

Phase 3 Completed

291 enrolled 22 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

USZ-STRIKE

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)